Skip to main content
. 2016 Oct 12;3(6):e289. doi: 10.1212/NXI.0000000000000289

Figure 2. Alemtuzumab-induced changes in the dendritic cell compartment.

Figure 2

(A) Gating strategy for dendritic cells. Peripheral blood mononuclear cells (PBMCs) were gated by forward scatter vs side scatter characteristics. Lineage (CD3, CD14, CD19) negative cells expressing human leukocyte antigen–DR (HLA-DR) were further categorized into CD141+ conventional DCs, CD1c+ conventional DCs, and CD303+ plasmacytoid dendritic cells (pDCs). (B) Graphs display proportions of Lin−HLA-DR+ cells within PBMCs or the respective dendritic cell (DC) subsets within Lin−HLA-DR+ (upper row) and total cell numbers (lower row) of DC subsets derived from alemtuzumab-treated patients with relapsing-remitting multiple sclerosis (n = 12) at baseline (filled triangles) and 6-month follow-up (open triangles). p Values were calculated by paired Student t test or Wilcoxon matched-pairs signed rank test, respectively, *p < 0.05, **p < 0.01, ***p < 0.001.